Co-Founder
Prior to co-founding Humanumeric, Paul was the President of Strategyst Consulting, Inc., and Managing Consultant of Strategic Forecasting & Quantitative Methods at the Mattson Jack Group, where he was responsible for the development of MJG’s modeling approach. During his 30 years of forecasting and modeling experience, he has worked in virtually every therapeutic area, and has deep experience in all types of quantitative decision support. He has created custom market models, epidemiology models, and forecasting platforms for dozens of pharmaceutical company clients, and has authored forecasting and Monte Carlo simulation software used by companies across the industry. Paul holds an M.Sci. in Theoretical Physics from the University of St. Andrews.
Co-Founder
Prior to co-founding Humanumeric, Kevin was a Senior Vice President with Kantar Health and MattsonJack, accumulating 15 years of experience in pharmaceutical market forecasting. With 30 years of experience in global commercial analytics and the pharmaceutical/biotech industry, he has been the lead architect and development director of pharmaceutical market forecasting software, has spoken at industry conferences, and conducted countless instructional workshops related to pharmaceutical market forecasting and oncology forecasting. He has also created custom market models, epidemiology models, and forecasting platforms for dozens of pharmaceutical company clients. Kevin holds a B.S.B.A. (Finance), magna cum laude, from the University of Missouri – St. Louis.
All of our epidemiology estimates are built upon a foundation of population projections by age, gender, and race/ethnicity (if relevant). Changing demographics and its impact on future population projections is one of the most-overlooked factors in forecasting.
We supplement your internal and proprietary sources by scouring publicly available sources to arrive at the best possible patient population estimates. Sources include published literature, as well as public and private datasets. Our unique ability to derive defendable estimates from seemingly disparate data sets us apart. This helps us paint a fuller picture of the patient journey, and uncovers hidden opportunities and pitfalls in the market.
We offer in-depth market analysis to help pharmaceutical companies understand industry trends, competitive landscape, as well as payer and consumer behavior.
Constructed a detailed forecast model of the Non-Small Cell Lung Cancer market that accounted for stage at diagnosis, patients' disease progression in both the adjuvant and metastatic settings, lines of therapy and treatment history, and genetic mutations both prior to and resulting from treatment.
Constructed population estimates for a rare genetic disorder. This then formed the foundation for a forecast model for a drug with an orphan indication, including the impact of genetic testing and gene therapy on the population.
Provided forecasting support for a currently marketed, multi-billion dollar product franchise. Integrated weekly data updates, constructed new Excel-based forecast models to improve forecasting process and accuracy for the brands, and provided support for strategic decision-making.